John T. Poirier

TL;DR: Exome, transcriptome and copy-number alteration data are obtained from approximately 53 samples consisting of 36 primary human SCLC and normal tissue pairs and 17 matched SCLCs and lymphoblastoid cell lines to identify several potential targets for therapeutic intervention.

TL;DR: This Opinion, written by many leading experts in small cell lung cancer (SCLC) research, proposes a new model of SCLC subtypes defined by differential expression of four key transcription regulators that should help to focus and accelerate therapeutic research.

TL;DR: Analysis of tumour samples and cell lines derived from resistant EGFR mutant patients revealed that Retinoblastoma (RB) is lost in 100% of these SCLC transformed cases, but rarely in those that remain NSCLC.

TL;DR: The authors targeted DLL3 with an antibody conjugated to a cytotoxic drug, which proved to be much more effective than standard chemotherapy for treating patient-derived tumor xenografts and is a promising first-in-class ADC for the treatment of high-grade pulmonary neuroendocrine tumors.

TL;DR: In this article, a combination of CRISPR-Cas9-based genetic screening and metabolomic analyses was used to identify mutations in the KEAP1 gene encoding Kelch-like ECH-associated protein 1 (KEAP1), a negative regulator of nuclear factor erythroid 2-like 2 (NFE2L2), which is the master transcriptional regulator of the endogenous antioxidant response.